{"id":12294,"date":"2023-10-30T21:15:00","date_gmt":"2023-10-30T13:15:00","guid":{"rendered":"https:\/\/flcube.com\/?p=12294"},"modified":"2024-11-12T21:19:55","modified_gmt":"2024-11-12T13:19:55","slug":"shanghai-pharmaceuticals-posts-13-11-yoy-revenue-growth-in-q3-2023-financials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=12294","title":{"rendered":"Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials"},"content":{"rendered":"\n

China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607<\/a>; SHA: 601607<\/a>) has released its financial results for the third quarter of 2023. The company recorded RMB 197.508 billion (USD 27 billion) in revenues over the nine-month period, marking a 13.11% year-on-year (YOY) increase. For Q3 alone, revenues reached RMB 64.9 billion (USD 8.88 billion), up 3.2% YOY.<\/p>\n\n\n\n

Industry and Commerce Sector Performance<\/strong>
During the 9-month period, the pharmaceutical industry and pharmaceutical commerce sectors generated RMB 20.8 billion (USD 2.85 billion) and RMB 176.708 billion (USD 24.2 billion), respectively, showing growth of 5.09% and 14.14% YOY. This robust performance underscores SPH’s strong position in both the manufacturing and distribution segments of the pharmaceutical market.<\/p>\n\n\n\n

Innovative Drug Pipelines and Clinical Trials<\/strong>
Shanghai Pharmaceuticals reported the addition of three new drug pipelines, including two innovative drugs. WST04, an oral probiotic preparation for the treatment of advanced malignant solid tumors, and I035, an immunomodulator that can inhibit intestinal inflammatory response and enhance intestinal immune regulation, are both currently under trial review in China. These additions highlight SPH’s commitment to innovation and expanding its therapeutic offerings.<\/p>\n\n\n\n

Pharmaceutical Distribution and Supply Chain Services<\/strong>
In the realm of pharmaceutical distribution and supply chain business, SPH provides comprehensive one-stop supply chain management services. These services encompass pre-market cooperation, import and export services, national distribution, and value-added services for innovative products for global pharmaceutical enterprises. During the first three quarters, the innovative drug sector saw a 21% YOY increase in sales, with the company signing up 21 products to act as a distributor in China.<\/p>\n\n\n\n

Conclusion<\/strong>
Shanghai Pharmaceuticals’ Q3 2023 financial results demonstrate the company’s continued growth and expansion in the pharmaceutical industry. With a focus on both innovative drug development and robust distribution services, SPH is well-positioned to meet the evolving needs of the global pharmaceutical market.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has released its financial…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,890,891,196],"class_list":["post-12294","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-hkg-2607","tag-sha-601607","tag-shanghai-pharmaceuticals"],"yoast_head":"\nShanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has released its financial results for the third quarter of 2023. The company recorded RMB 197.508 billion (USD 27 billion) in revenues over the nine-month period, marking a 13.11% year-on-year (YOY) increase. For Q3 alone, revenues reached RMB 64.9 billion (USD 8.88 billion), up 3.2% YOY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=12294\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=12294\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-30T13:15:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-12T13:19:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12294#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12294\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials\",\"datePublished\":\"2023-10-30T13:15:00+00:00\",\"dateModified\":\"2024-11-12T13:19:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12294\"},\"wordCount\":297,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"HKG: 2607\",\"SHA: 601607\",\"Shanghai Pharmaceuticals\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12294#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12294\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=12294\",\"name\":\"Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-10-30T13:15:00+00:00\",\"dateModified\":\"2024-11-12T13:19:55+00:00\",\"description\":\"China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has released its financial results for the third quarter of 2023. The company recorded RMB 197.508 billion (USD 27 billion) in revenues over the nine-month period, marking a 13.11% year-on-year (YOY) increase. For Q3 alone, revenues reached RMB 64.9 billion (USD 8.88 billion), up 3.2% YOY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12294#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12294\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12294#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials - Insight, China's Pharmaceutical Industry","description":"China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has released its financial results for the third quarter of 2023. The company recorded RMB 197.508 billion (USD 27 billion) in revenues over the nine-month period, marking a 13.11% year-on-year (YOY) increase. For Q3 alone, revenues reached RMB 64.9 billion (USD 8.88 billion), up 3.2% YOY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=12294","og_locale":"en_US","og_type":"article","og_title":"Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=12294","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-10-30T13:15:00+00:00","article_modified_time":"2024-11-12T13:19:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=12294#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=12294"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials","datePublished":"2023-10-30T13:15:00+00:00","dateModified":"2024-11-12T13:19:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=12294"},"wordCount":297,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","HKG: 2607","SHA: 601607","Shanghai Pharmaceuticals"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=12294#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=12294","url":"https:\/\/flcube.com\/?p=12294","name":"Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-10-30T13:15:00+00:00","dateModified":"2024-11-12T13:19:55+00:00","description":"China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has released its financial results for the third quarter of 2023. The company recorded RMB 197.508 billion (USD 27 billion) in revenues over the nine-month period, marking a 13.11% year-on-year (YOY) increase. For Q3 alone, revenues reached RMB 64.9 billion (USD 8.88 billion), up 3.2% YOY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=12294#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=12294"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=12294#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12294"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12294\/revisions"}],"predecessor-version":[{"id":12295,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12294\/revisions\/12295"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}